Sign in
4

Changes in Ownership

Protalix BioTherapeutics, Inc. Filed Acc 0001104659-22-098949

Options or other derivatives

  • President and CEO acquired 750,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Bashan Dror President and CEO 2022-09-07 Grant or award · Stock Options (Right to Buy) +750,000 750,000 D
Loading xslF345X03/tm2225460-6_4seq1.xml…